Merck & Co
Latest statistics and disclosures from Merck & Co's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PSNL, MRNA, KYMR, ALEC, Entrada Therapeutics, and represent 94.50% of Merck & Co's stock portfolio.
- Merck & Co has $228M in assets under management (AUM), dropping by 5.77%.
- Central Index Key (CIK): 0000310158
Tip: Access up to 7 years of quarterly data
Positions held by Merck & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Merck & Co
Merck & Co holds 13 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Personalis Ord (PSNL) | 40.2 | $92M | 14M | 6.52 |
|
|
| Moderna (MRNA) | 26.1 | $60M | 2.3M | 25.83 |
|
|
| Kymera Therapeutics (KYMR) | 19.2 | $44M | 772k | 56.60 |
|
|
| Alector (ALEC) | 4.6 | $11M | 3.5M | 2.96 |
|
|
| Entrada Therapeutics | 4.4 | $10M | 1.7M | 5.80 |
|
|
| Evaxion Biotech A/s Sponsored Ads | 2.0 | $4.6M | 1.2M | 3.76 |
|
|
| Sutro Biopharma (STRO) | 1.0 | $2.4M | 2.7M | 0.87 |
|
|
| Miragen Therapeutics (VRDN) | 0.9 | $2.0M | 93k | 21.58 |
|
|
| Lava Therapeutics Nv SHS (LVTX) | 0.8 | $1.8M | 1.1M | 1.56 |
|
|
| Xilio Therapeutics (XLO) | 0.5 | $1.3M | 1.5M | 0.84 |
|
|
| Carisma Therapeutics (CARM) | 0.2 | $404k | 1.5M | 0.27 |
|
|
| Neuphoria Therapeutics (NEUP) | 0.1 | $118k | 10k | 11.79 |
|
|
| Tuhura Biosciences (HURA) | 0.0 | $35k | 14k | 2.48 |
|
Past Filings by Merck & Co
SEC 13F filings are viewable for Merck & Co going back to 2025
- Merck & Co 2025 Q3 filed Nov. 12, 2025
- Merck & Co 2025 Q2 filed Aug. 13, 2025